Thomas F. Gajewski

12.9k total citations · 3 hit papers
33 papers, 9.4k citations indexed

About

Thomas F. Gajewski is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Thomas F. Gajewski has authored 33 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Immunology, 17 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Thomas F. Gajewski's work include Immunotherapy and Immune Responses (27 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Immune Cell Function and Interaction (12 papers). Thomas F. Gajewski is often cited by papers focused on Immunotherapy and Immune Responses (27 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Immune Cell Function and Interaction (12 papers). Thomas F. Gajewski collaborates with scholars based in United States, Belgium and Qatar. Thomas F. Gajewski's co-authors include Yang‐Xin Fu, Hans Schreiber, Stefani Spranger, Riyue Bao, Seng‐Ryong Woo, Mercedes B. Fuertes, Leticia Corrales, Justin Kline, Aalok Kacha and Kenneth M. Murphy and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Thomas F. Gajewski

33 papers receiving 9.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Innate and adaptive immune cells in the tumor microenvironment

2013 3.1k citations Thomas F. Gajewski, Hans Schreiber et al. Nature Immunology profile →
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

2015 2.0k citations Stefani Spranger, Riyue Bao et al. Nature profile →
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells

2011 937 citations Mercedes B. Fuertes, Aalok Kacha et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas F. Gajewski United States	23	6.0k	5.4k	2.8k	1.1k	1.0k	33	9.4k
Miguel F. Sanmamed Spain	40	5.0k 0.8×	5.6k 1.0×	2.5k 0.9×	1.5k 1.3×	1.1k 1.1×	115	9.3k
Stefani Spranger United States	40	7.5k 1.3×	7.5k 1.4×	3.7k 1.3×	1.3k 1.1×	1.3k 1.3×	80	12.2k
Eyad Elkord United Kingdom	41	3.9k 0.6×	4.3k 0.8×	2.2k 0.8×	1.1k 1.0×	950 0.9×	126	7.7k
Brian Ruffell United States	33	7.1k 1.2×	5.3k 1.0×	3.4k 1.2×	1.0k 0.9×	1.5k 1.4×	53	10.7k
Chiara Castelli Italy	46	5.8k 1.0×	4.8k 0.9×	4.4k 1.6×	664 0.6×	1.3k 1.2×	127	10.2k
Nathalie Chaput France	45	5.6k 0.9×	5.7k 1.1×	4.5k 1.6×	1.6k 1.4×	1.8k 1.7×	144	11.7k
Inge Marie Svane Denmark	56	6.7k 1.1×	7.2k 1.3×	3.3k 1.2×	840 0.7×	622 0.6×	385	11.0k
Sergio A. Quezada United Kingdom	45	7.5k 1.3×	7.5k 1.4×	3.0k 1.0×	1.8k 1.6×	1.6k 1.5×	97	12.6k
Yoshiko Iwai Japan	21	6.8k 1.1×	7.1k 1.3×	1.8k 0.6×	1.2k 1.0×	586 0.6×	30	10.7k
Hua Liang China	29	4.1k 0.7×	4.1k 0.8×	2.2k 0.8×	1.2k 1.1×	626 0.6×	79	7.9k

Countries citing papers authored by Thomas F. Gajewski

Since Specialization

Citations

This map shows the geographic impact of Thomas F. Gajewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas F. Gajewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas F. Gajewski more than expected).

Fields of papers citing papers by Thomas F. Gajewski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas F. Gajewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas F. Gajewski. The network helps show where Thomas F. Gajewski may publish in the future.

Co-authorship network of co-authors of Thomas F. Gajewski

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas F. Gajewski. A scholar is included among the top collaborators of Thomas F. Gajewski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas F. Gajewski. Thomas F. Gajewski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sweis, Randy F., Stefani Spranger, Riyue Bao, et al.. (2016). Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunology Research. 4(7). 563–568. 235 indexed citations

Lei, Yuk Man, Luqiu Chen, Ying Wang, et al.. (2016). The composition of the microbiota modulates allograft rejection. Journal of Clinical Investigation. 126(7). 2736–2744. 80 indexed citations

Luke, Jason J., et al.. (2016). Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial. Journal for ImmunoTherapy of Cancer. 4(1). 35–35. 21 indexed citations

Bedognetti, Davide, Ileana S. Mauldin, Donna H. Deacon, et al.. (2016). Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. OncoImmunology. 5(12). e1240857–e1240857. 51 indexed citations

Corrales, Leticia, Vyara Matson, Blake Flood, Stefani Spranger, & Thomas F. Gajewski. (2016). Innate immune signaling and regulation in cancer immunotherapy. Cell Research. 27(1). 96–108. 302 indexed citations

Spranger, Stefani, Riyue Bao, & Thomas F. Gajewski. (2015). Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 523(7559). 231–235. 1958 indexed citations breakdown →

Sweis, Randy F., Stefani Spranger, & Thomas F. Gajewski. (2015). Molecular drivers of the non-T cell-inflamed tumor microenvironment in urothelial bladder cancer.. Journal of Clinical Oncology. 33(15_suppl). 4511–4511. 19 indexed citations

Yang, Xuanming, et al.. (2014). Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses. Cancer Cell. 25(1). 37–48. 230 indexed citations

Zhang, Long, Xiufen Chen, Xiao Liu, et al.. (2013). CD40 ligation reverses T cell tolerance in acute myeloid leukemia. Journal of Clinical Investigation. 123(5). 1999–2010. 58 indexed citations

10.

Gajewski, Thomas F., Hans Schreiber, & Yang‐Xin Fu. (2013). Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology. 14(10). 1014–1022. 3122 indexed citations breakdown →

11.

Gajewski, Thomas F., Seng‐Ryong Woo, Yuanyuan Zha, et al.. (2013). Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Current Opinion in Immunology. 25(2). 268–276. 341 indexed citations

12.

Gajewski, Thomas F.. (2012). Cancer immunotherapy. Molecular Oncology. 6(2). 242–250. 62 indexed citations

13.

Fuertes, Mercedes B., et al.. (2012). Type I interferon response and innate immune sensing of cancer. Trends in Immunology. 34(2). 67–73. 276 indexed citations

14.

Fuertes, Mercedes B., Aalok Kacha, Justin Kline, et al.. (2011). Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. The Journal of Experimental Medicine. 208(10). 2005–2016. 937 indexed citations breakdown →

15.

Peterson, Amy, et al.. (2008). The HLA‐A2‐restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. The Prostate. 69(2). 142–148. 9 indexed citations

16.

Harlin, Helena, et al.. (2006). Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites. Cancer Immunology Immunotherapy. 55(10). 1185–1197. 111 indexed citations

17.

Roberts, John D., Donna Niedzwiecki, William E. Carson, et al.. (2005). Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma. Journal of Immunotherapy. 29(1). 95–101. 16 indexed citations

18.

Fallarino, Francesca, Catherine Uyttenhove, Thierry Boon, & Thomas F. Gajewski. (1999). Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. International Journal of Cancer. 80(2). 324–333. 54 indexed citations

19.

Warnier, Guy, Catherine Uyttenhove, Thomas F. Gajewski, et al.. (1996). Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A. International Journal of Cancer. 67(2). 303–310. 47 indexed citations

20.

Boon, Thierry, Thomas F. Gajewski, & Pierre G. Coulie. (1995). From defined human tumor antigens to effective immunization?. Immunology Today. 16(7). 334–336. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact